Lilly licenses anticancer drug simulation model
This article was originally published in Scrip
Executive Summary
Lilly has licensed Physiomics' "ModelPlayer", a platform that predicts the efficacy of anticancer candidates, for unspecified targets. Financial details were not disclosed.